AHernando_Calvo
@AhernandoCalvo
Followers
328
Following
511
Media
11
Statuses
248
Clinician scientist at @vallhebron Phase 1 and Cancer Genomics Group @VHIO. Former med onc fellow at @pmcancercentre, Phase1/Head and Neck, biomarkers.
Joined March 2020
Thank you @myESMO for highlighting our recent publication in @eClinicalMed unveiling dowstream effects of performing #NGS in pts with advanced solid tumors enrolled in OCTANE. Very nice summary! 👇 https://t.co/MMu8S2Bl0e 👇 https://t.co/7JNk2C3lmF
thelancet.com
We found an increase in healthcare costs associated with multi-gene panel testing for advanced cancer treatment. The impact on OS was not significant, but varied across tumor types. OCTANE was...
0
1
15
Thanks for the mention @CataniGreta! A true pleasure working with you under the expert guidance of @AhernandoCalvo and the rest of the @VHIO team. Thrilled to share our review on biomarkers in early-phase immunotherapy trials!
Our review on biomarker enrichment in early-phase immunotherapy trials is out in @FrontiersIn Grateful to collaborate with @dmorchon95 and especially for the mentorship and guidance of @AhernandoCalvo, who made this work possible https://t.co/ca26OBMdy7
0
1
3
Our review on biomarker enrichment in early-phase immunotherapy trials is out in @FrontiersIn Grateful to collaborate with @dmorchon95 and especially for the mentorship and guidance of @AhernandoCalvo, who made this work possible https://t.co/ca26OBMdy7
frontiersin.org
Immune checkpoint inhibitors have revolutionized the treatment of solid tumors; however, their clinical efficacy remains limited to a subset of patients. Nov...
2
1
5
Happy to see this finally out! Humbled by the support from my former mentors at @pmcancercentre and Marc Oliva at @ICO_oncologia. An international collaboration including ultra-rare sinonasal cancers. 📌Now that we understand the prognostic factors, let's find druggable targets
👉🏼 Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled Analysis - by Stefanovic & @AhernandoCalvo - The Laryngoscope - a collab between @pmcancercentre &@ICO_oncologia. @FundacionTTCC @ttccgroup
1
2
5
Check out our latest review in collaboration with @VHIO @vallhebron team during my observership, funded by a @_SEOM grant. Congrats to first co-author @CataniGreta and special thanks to @AhernandoCalvo for the mentorship @IBSAL_IIS @IAF_Fleming @IJMS_MDPI
https://t.co/EjZPV30Ds5
mdpi.com
Immunotherapy has significantly changed the treatment paradigm for solid tumors, with immune checkpoint inhibitors now established in the management of many malignancies. Despite initial success,...
2
7
15
@drenriquegrande !! 11 años avanzando en la oncología de precisión y aplicando la genómica al día a día! Un lujo contar con un panel de ponentes brutal !! Pero dejad que me 🤤 con mis amigos del @VHIO que se han salido como siempre! @rdienstmann @JHernando3 @AhernandoCalvo 🙌🏼👏🏼
0
4
15
🔬Esta semana hemos sabido que un estudio de @Genomicslab_ y la #UITM-@CaixaResearch del VHIO muestra que combinar la firma génica #VIGex con #biopsialíquida mejora la predicción de respuesta a inmunoterapia en tumores sólidos avanzados. ➕ https://t.co/HPx7VEXuwv
#CAIMI #DIAMAV
0
3
10
🧑🏻⚕️ @AhernandoCalvo , @vallhebron, #UITM @CaixaResearch i @Genomicslab_ VHIO, rep una beca @GileadSciences per validar l’eina #VIGex com a biomarcador de resposta a la immunoteràpia en assajos de fase primerenca 👏 Enhorabona ‼️ ➕ https://t.co/F9V4uac5TM
0
1
4
📍Happy to share this publication @JCOPO_ASCO validating VIGex signature in the INSPIRE trial. Improved predictive performance for IO benefit was observed with VIGex+ctDNA dynamics in this international collaboration 🇨🇦 🇪🇸@pmcancercentre @VHIO @vallhebron
ascopubs.org
PURPOSEImmune gene expression signatures are emerging as potential biomarkers for immunotherapy (IO). VIGex is a 12-gene expression classifier developed in both nCounter (Nanostring) and RNA sequen...
0
3
17
Phase II, open-label, randomized trial of durvalumab with olaparib or cediranib in pts with pMMR CRC or pancreatic cancer at @pmcancercentre. Mentorship from Aaron Hansen and @lillian_siu and support from @PughLab @bhaibeka labs @OICR_news and others! https://t.co/0PDKCte0Nu
1
2
12
Findings from a first-in-human phase I study investigating IBI363 - @ESMO
@AhernandoCalvo @vallhebron @VHIO @pmcancercentre
https://t.co/ZWv1GmyFJt
#Cancer #ESMO #ESMODailyReporter #ESMOVirtualPlenary #Melanoma #OncoDaily #Oncology
0
3
25
📍Stay tuned for today´s session with both clinical insights and AACR expert commentary
Missed yesterday's session? 👉 Stay up to date with innovative #immunotherapy approaches and engage with the panel of expert presenters by submitting your questions live. #ESMOVirtualPlenary 🔗 https://t.co/C10evb5Nkp
0
0
4
#ESMOVirtualPlenary: Safety & efficacy of a PD-1/IL-2 bispecific antibody fusion protein show proof-of-concept on its capacity to overcome resistance to #immunotherapy in pre-treated pts & some populations w/ poor prognosis. #ESMODailyReporter 👉 https://t.co/GoHFhUXgZm
0
1
5
Almost starting #ASCO24, and receiving the news that our review in new therapies (ADC, BsAbs) for H&N SCC and nasopharyngeal carcinoma is finally published in Cancer Treatment Reviews! Congrats to all co-authors! 👏#HNCSM @royalmarsdenNHS @VHIO
https://t.co/bjqsBfX689
2
6
16
Happy to share our last review in Cancer Treatment Reviews. Big support from @AliceRossiMD , Maria Vieito, Emile Voest @NKI_nl and Elena Garralda @VHIO 🙌Exciting times for tumor agnostic therapies but also many challenges lying ahead https://t.co/wPa6uXiYDG
0
4
11
AACR members have elected #AACRFellows Lillian L. Siu, MD, as their 2024-2025 President-Elect. Dr. Siu will become President-Elect on April 8 during the #AACR24 Business Meeting of Members and will assume the Presidency during #AACR25. https://t.co/IV413DwS1p
16
32
145
Happening now at @WIN_Consortium. Potential applications of AI in liquid biopsies an precission oncology. We are only in the tip of the iceberg.
0
1
2
Great to see colleagues from Tokyo, VHIO in Barcelona, Kinghorn in Australia and Fudan University in Shanghai. @WIN_Consortium Symposium in Abu Dhabi
0
4
5
📡Happening now at @WIN_Consortium 2024 symposium in @AbuDhabi_ADM. Amazing efforts within the the Emirati Genome Program led by @ikjow with over 50.000 genomes profiled. So far, no arab genomes are being used as reference for mutation variant calling. Limitation to be aware 🧐
0
0
1
Keynote lecture from Prof @weldeiry new chair at @WIN_Consortium 2024 symposium in @AbuDhabi_ADM . Importance of the Tumor Board and n-of-1 clinical trials for personalizing cancer care and the success history of the WINTHER trial where @VHIO had a pivotal role
0
7
9